TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06812078: A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH)

Sponsor: Takeda · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 96 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,062,400

Rescue Site Savings

+$697,200

Unlock Full NCT06812078 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06812078 Rescue Dossier →